亞太地區基於細胞片的基因治療市場：按技術類型、細胞片類型、來源、用途、最終用戶和國家進行分析（2025 年至 2035 年）

亞太地區以細胞片為基礎的基因治療市場預計將從 2024 年的 1.708 億美元成長到 2035 年的 8.79 億美元，預測期內的複合年成長率為 16.06%。

全球再生醫學公司正積極進軍該地區，與本地先驅企業攜手成為主要企業的市場驅動力。 CellSeed Inc.（日本）和J-TEC（日本組織工程株式會社）等領先主要企業擁有強大的臨床開發平臺和針對眼科、食道和心臟再生的近乎上市的治療方法。這些公司受益於日本政府對再生醫學的大力支持和先進的監管體系，這促進了市場擴張和創新。

在組織工程學的進步和再生醫學日益成長的需求的推動下，亞洲基於細胞片層的基因治療市場正在穩步成長。這種創新的治療方法結合了基因修飾和細胞片層技術，無需支架即可實現標靶組織修復，同時保留細胞外基質和細胞間黏附。中國、韓國和日本等國家在先進生物製藥投資不斷增加以及良好的法規環境的推動下，處於研究和商業化的前沿。

尤其是日本，憑藉其先進的再生醫學法規結構，在皮膚修復、角膜修復、食道重組和心肌再生等臨床應用方面取得了進展。韓國正在拓展其生物技術基礎設施，同時注重精密製造和國際夥伴關係。中國也迅速適應國際標準，以促進國內創新並發展臨床研發管線。

人口老化、慢性病發生率上升以及政府加大對生技研發投入等因素也在推動市場擴張。然而，複雜的製造流程、高成本以及不同地區監管體系的差異等挑戰可能會阻礙市場擴張。然而，隨著技術創新的不斷推進、產學研合作的不斷推進以及區域監管協調舉措的推進，亞太地區有望成為未來基因和細胞治療的主要樞紐。

市場區隔:

細分一：按技術類型

• 細胞片層工程
  • 光誘導細胞片技術
  • 溫度響應培養表面
  • 無支架技術
  • 逐層組裝
  • 其他技術
• 基因轉移方法
  • 基於病毒載體的方法（例如慢病毒、腺病毒）
  • 非病毒載體方法（例如脂質體、奈米粒子）
  • CRISPR/Cas9
  • 其他基因轉移方法

細分2：按細胞片類型

• 單層細胞片
• 共培養細胞片
• 多層細胞片
• 其他

細分3：按來源地

• 自體
• 同源
• 幹細胞衍生

細分 4：按應用

• 瘤
• 眼科
• 遺傳性疾病
• 心臟病學
• 其他

細分 5：按最終用戶

• 醫院和診所
• 研究和學術機構
• 生物技術和製藥公司
• 其他

細分6：按地區

• 亞太地區
  • 日本
  • 印度
  • 中國
  • 澳洲
  • 韓國
  • 其他

本報告調查了亞太地區基於細胞片的基因治療市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、技術和專利分析、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章基於細胞片的基因治療市場：產業展望

• 基於細胞片的基因治療市場趨勢
  • 再生醫學與基因工程的新融合
• 競爭格局
  • 商業策略
  • 企業策略
• 認證核可藥：利用細胞片的基因治療
• 研發藥物：基於細胞片的基因治療
• 監管狀況
  • 亞太地區
• 市場動態
  • 趨勢、促進因素、挑戰和機會：評估當前和未來的影響
  • 市場促進因素
  • 市場限制
  • 市場機會
• 市場挑戰
  • 監理核准和道德問題

第2章 細胞片基因治療市場（按地區）

• 區域摘要
• 亞太地區
  • 區域概況
  • 市場成長動力
  • 市場問題
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 其他

第3章調查方法

This report can be delivered in 2 working days.

Introduction to Asia-Pacific (APAC) Cell Sheet-based Gene Therapy Market

The Asia-Pacific cell sheet-based gene therapy market is projected to reach $879.0 million by 2035 from $170.8 million in 2024, growing at a CAGR of 16.06% during the forecast period 2025-2035. Global regenerative medicine businesses aggressively extending their footprint and regional pioneers are major players in the APAC cell sheet-based gene therapy market. Leading companies in the field, including CellSeed Inc. (Japan) and J-TEC (Japan Tissue Engineering Co., Ltd.), have robust clinical pipelines and treatments that are ready for the market that target ocular, esophageal, and cardiac regeneration. These businesses profit from Japan's robust government backing for regenerative medicine and its innovative regulatory framework.

Temperature-responsive culture dishes are used by CellSeed Inc. to produce autologous cell sheet products, and J-TEC has created and marketed a number of autologous cell-based goods, such as skin and cartilage repair products. Scalable clinical deployment throughout Asia is supported by their integrated R&D and GMP-compliant production facilities.

In the meantime, further funding and collaborations are being made in nations like China and South Korea with the goal of commercializing gene-modified cell sheets for uncommon ocular and dermatological disorders. Through strategic partnerships between academia, government, and the commercial sector, biotech firms and institutions around the area are placing an emphasis on translational research and industrial scalability.

These advancements establish APAC as a competitive center for next-generation cell sheet-based gene treatments and demonstrate the region's expanding significance in fostering innovation for complicated epithelium and tissue regeneration therapies.

Market Introduction

The market for cell sheet-based gene therapy in Asia is expanding steadily because to advances in tissue engineering and the growing need for regenerative medicine. This novel therapeutic strategy maintains the integrity of the extracellular matrix and cell-to-cell connections while enabling targeted tissue repair without the need for scaffolds through the combination of genetic alteration and cell sheet technology. With the help of advantageous regulatory environments and rising investments in cutting-edge biologics, nations like China, South Korea, and Japan are leading the way in research and commercialization.

Clinical applications in skin healing, corneal restoration, esophagus reconstruction, and cardiac regeneration have advanced due to Japan's innovative position in regulating regenerative medicine. With a focus on precision manufacturing and global partnerships, South Korea is also growing its biotech infrastructure. Furthermore, in an effort to foster domestic innovation and develop clinical pipelines, China is quickly bringing itself into compliance with international norms.

Market expansion is also supported by aging populations, the growing burden of chronic diseases, and greater government investment for biotechnology R&D. Scalability may be hampered by issues including intricate manufacturing procedures, exorbitant expenses, and regionally disparate regulations. Notwithstanding these obstacles, ongoing technological advancements, collaborations between academia and business, and regional harmonization initiatives are establishing Asia-Pacific as a major center for gene and cell therapies of the future.

Market Segmentation

Segmentation 1: By Technology Type

• Cell sheet-based Engineering Techniques
  • Light-induced cell sheet technology
  • Temperature-Responsive Culture Surfaces
  • Scaffold-Free Techniques
  • Layer-by-Layer Assembly
  • Other Techniques
• Gene Delivery Methods
  • Viral Vector-Based (e.g., Lentivirus, Adenovirus)
  • Non-Viral Vector-Based (e.g., Liposomes, Nanoparticles)
  • CRISPR/Cas9
  • Other Gene Delivery Methods

Segmentation 2: By Cell-Sheet Type

• Monolayer Cell-sheet Type
• Co-culture Cell-sheet Type
• Multilayered Cell-sheet Type
• Others

Segmentation 3: By Source Type

• Autologous
• Allogenic
• Stem-cell Derived

Segmentation 4: By Application

• Oncology
• Ophthalmology
• Genetic Disorders
• Cardiology
• Others

Segmentation 5: By End-User

• Hospitals and Clinics
• Research and Academic Institutions
• Biotech and Pharma Companies
• Others

Segmentation 6: By Region

• Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest-of-Asia-Pacific

APAC Cell Sheet-Based Gene Therapy Market Trends, Drivers and Challenges

Market Trends

• Rapid growth of the cell and gene therapy sector in the

APAC region, supported by increasing clinical trials and commercial interest.

• Rising adoption of autologous therapies, especially for oncology, genetic, and regenerative applications.
• Strong innovation pipeline in countries like Japan, South Korea, and China for late-stage cell sheet therapies targeting cartilage, ocular, and skin tissues.

Market Drivers

• Growing burden of chronic, genetic, and age-related diseases is increasing demand for regenerative therapies.
• Supportive regulatory initiatives and fast-track approval mechanisms in key APAC countries are encouraging development and commercialization.
• Expanding public-private partnerships and infrastructure investments are boosting manufacturing capacity and clinical translation.

Market Challenges

• High production and operational costs for cell sheet-based therapies limit affordability and accessibility.
• Fragmented regulatory requirements across the region create hurdles for cross-border clinical and commercial integration.
• Shortage of skilled talent in advanced cell therapy manufacturing and quality control remains a key bottleneck.

Market Opportunities

• Integration of automation and AI-driven quality control to streamline production and reduce time to market.
• Expansion of contract manufacturing organizations (CMOs) and academic-industry collaborations to scale innovation.
• Increasing focus on personalized medicine and precision therapies is creating demand for novel cell-based platforms.

How can this report add value to an organization

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in APAC cell sheet-based gene therapy, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new APAC cell sheet-based gene therapy.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Table of Contents

Executive Summary

Scope and Definition

1 Cell sheet-based Gene Therapy Market: Industry Outlook

• 1.1 Trends in Cell Sheet-based Gene Therapy Market
  • 1.1.1 Emerging Convergence of Regenerative Medicine and Genetic Engineering
• 1.2 Competitive Landscape
  • 1.2.1 Business Strategies
    • 1.2.1.1 Product Developments
  • 1.2.2 Corporate Strategies
    • 1.2.2.1 Partnerships and Joint Ventures
• 1.3 Approved Drugs, Cell sheet-based Gene Therapy
• 1.4 Pipeline Drugs, Cell sheet-based Gene Therapy
• 1.5 Regulatory Landscape
  • 1.5.1 Asia-Pacific
    • 1.5.1.1 Japan
    • 1.5.1.2 China
    • 1.5.1.3 South Korea
• 1.6 Market Dynamics
  • 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • 1.6.2 Market Drivers
    • 1.6.2.1 Advancement in Regenerative Medicine
    • 1.6.2.2 Growing Investment in Personalized Medicine
    • 1.6.2.3 Technological Advancements in Cell Sheet Therapy
  • 1.6.3 Market Restraints
    • 1.6.3.1 Rising Cost of Development and Manufacturing
  • 1.6.4 Market Opportunities
    • 1.6.4.1 Substantial Surge in the Rise of Cell Sheet Approaches
    • 1.6.4.2 Rising Application for Localized and Minimally Invasive Treatments
• 1.7 Market Challenges
  • 1.7.1 Regulatory Approval and Ethical Issues

2 Cell Sheet-based Gene Therapy Market (by Region), Value ($million), 2023-2035

• 2.1 Regional Summary
• 2.2 Asia-Pacific
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Japan
  • 2.2.5 China
  • 2.2.6 India
  • 2.2.7 Australia
  • 2.2.8 South Korea
  • 2.2.9 Rest-of-Asia-Pacific

3 Research Methodology

• 3.1 Data Sources
  • 3.1.1 Primary Data Sources
  • 3.1.2 Secondary Data Sources
  • 3.1.3 Inclusion and Exclusion
  • 3.1.4 Data Triangulation
• 3.2 Market Estimation and Forecast

List of Figures

• Figure 1: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Scenario), $Million, 2024, 2028, and 2035
• Figure 2: Asia-Pacific Cell Sheet-based Gene Therapy Market, 2024-2035
• Figure 3: Asia-Pacific Cell Sheet-based Gene Therapy Market Snapshot
• Figure 4: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Technology Type), $Million, 2024, 2028, and 2035
• Figure 5: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Cell-Sheet Type), $Million, 2024, 2028, and 2035
• Figure 6: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Source Type), $Million, 2024, 2028, and 2035
• Figure 7: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Application Type), $Million, 2024, 2028, and 2035
• Figure 8: Asia-Pacific Cell Sheet-based Gene Therapy Market (by End User), $Million, 2024, 2028, and 2035
• Figure 9: Japan Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 10: China Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 11: India Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 12: Australia Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 13: South Korea Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 14: Rest of Asia-Pacific Cell Sheet-based Gene Therapy Market, $Million, 2023-2035
• Figure 15: Inclusion and Exclusion Criteria for Cell Sheet-based Gene Therapy Market
• Figure 16: Data Triangulation
• Figure 17: Top-Down and Bottom-Up Approach
• Figure 18: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Approved Drugs in Cell-Sheet based Gene Therapy Market
• Table 3: Pipeline Drugs in Cell-Sheet based Gene Therapy Market
• Table 4: Cell Sheet-based Gene Therapy Market (by Region), $Million, 2023-2035
• Table 5: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Technology Type), $Million, 2023-2035
• Table 6: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Cell sheet-based Engineering Techniques Type), $Million, 2023-2035
• Table 7: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Gene Delivery Methods), $Million, 2023-2035
• Table 8: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Cell-sheet Type), $Million, 2023-2035
• Table 9: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Source Type), $Million, 2023-2035
• Table 10: Asia-Pacific Cell Sheet-based Gene Therapy Market (by Application Type), $Million, 2023-2035
• Table 11: Asia-Pacific Cell Sheet-based Gene Therapy Market (by End User), $Million, 2023-2035